<DOC>
	<DOC>NCT02640729</DOC>
	<brief_summary>This study seeks to evaluate safety and efficacy of Nelotanserin for the treatment of visual hallucinations in subjects with Lewy body dementia.</brief_summary>
	<brief_title>Study Evaluating Nelotanserin for Treatment of Visual Hallucinations in Subjects With Lewy Body Dementia</brief_title>
	<detailed_description>This is a double-blind, randomized, placebo-controlled, cross-over study in subjects with Lewy body dementia who experience frequent visual hallucinations. Subjects who meet the randomization criteria enter the double-blind treatment period. Each subject will be randomized 1:1 to one of the 2 treatment sequences: Nelotanserin in the first treatment period followed by placebo in the second treatment period, or placebo in the first treatment period followed by Nelotanserin in the second treatment period.</detailed_description>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Hallucinations</mesh_term>
	<mesh_term>Lewy Body Disease</mesh_term>
	<criteria>Adult subjects aged 5085, inclusive, with a diagnosis of LBD based on DSM5 diagnostic criteria or diagnosis of Parkinson's disease dementia (PDD) based on DSM5 diagnostic criteria; Presence of frequent visual hallucinations Mini Mental State Examination score â‰¥ 18 Subjects have a current diagnosis of significant psychotic disorders including, but not limited to, schizophrenia or bipolar disorder Subjects' psychotic symptoms are secondary to or better accounted for by another medical condition, psychiatric disorder, or substance abuse Subjects with a current serious and/or unstable cardiovascular, respiratory, thyroid, gastrointestinal, renal, hematologic or other medical disorder</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Lewy body dementia</keyword>
	<keyword>Dementia with Lewy bodies</keyword>
	<keyword>Parkinson's disease dementia</keyword>
	<keyword>Lewy bodies</keyword>
	<keyword>Visual hallucinations</keyword>
</DOC>